Company News

An image of DNA signifying the genetic cause.

     ReflectionBio – By Patients, For Patients ®

Company News

ReflectionBio joins forces with patient organization Invincible Vision ahead of World Rare Disease Day for Bietti’s Crystalline Dystrophy (BCD)

SAN FRANCISCO & HONG KONG–(BUSINESS WIRE)–Today, Invincible Vision and ReflectionBio® are launching their inaugural awareness and fundraising campaign, BY PATIENTS, FOR PATIENTS ™, for Bietti’s Crystalline Dystrophy (BCD).

VIEW MORE
Rare Disease Patient CEO Joins “Orphan Drug Development Guidebook” Task Force

Richard Yang, Founder & CEO of ReflectionBio and a rare disease patient, was invited to join the newly formed “Orphan Drug Development Guidebook” Task Force of International Rare Diseases Research Consortium (IRDiRC).

VIEW MORE
Patient-Driven Gene Therapy Company ReflectionBio® Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD).

HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S.

VIEW MORE